1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Wet (Neovascular / Exudative) Macular Degeneration-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Wet (Neovascular / Exudative) Macular Degeneration-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Wet (Neovascular / Exudative) Macular Degeneration Report is to understand the market and pipeline status of the drugs around the Wet (Neovascular / Exudative) Macular Degeneration to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Wet (Neovascular / Exudative) Macular Degeneration. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Wet (Neovascular / Exudative) Macular Degeneration.
- A review of the marketed products under prescription for Wet (Neovascular / Exudative) Macular Degeneration, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Wet (Neovascular / Exudative) Macular Degeneration with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Wet (Neovascular / Exudative) Macular Degeneration drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Wet (Neovascular / Exudative) Macular Degeneration drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Wet (Neovascular / Exudative) Macular Degeneration drugs.
- Coverage of Wet (Neovascular / Exudative) Macular Degeneration Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Wet (Neovascular / Exudative) Macular Degeneration key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Wet (Neovascular / Exudative) Macular Degeneration.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Wet (Neovascular / Exudative) Macular Degeneration.
- API intelligence over marketed drugs forWet (Neovascular / Exudative) Macular Degenerationand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Wet (Neovascular / Exudative) Macular Degeneration.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Wet (Neovascular / Exudative) Macular Degeneration-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Wet (Neovascular / Exudative) Macular Degeneration
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Wet (Neovascular / Exudative) Macular Degeneration
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Wet (Neovascular / Exudative) Macular Degeneration
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, (Year), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, Europe by Country, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, India by State, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, China by Province, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers by Geography 2017
- Wet (Neovascular / Exudative) Macular Degeneration Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Wet (Neovascular / Exudative) Macular Degeneration, 2017
- Discontinued Drugs for Wet (Neovascular / Exudative) Macular Degeneration, 2017


List of Figures

- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, US, (Year), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, Europe by Country, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, India by State, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers, China by Province, 2017
- Wet (Neovascular / Exudative) Macular Degeneration Drugs, API Manufacturers by Geography 2017
- Wet (Neovascular / Exudative) Macular Degeneration Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Wet (Neovascular / Exudative) Macular Degeneration Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Glaucoma Therapeutics Market: Overview Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma ...

Europe Market Report for Corneal Topographers 2017 - MedCore

Europe Market Report for Corneal Topographers 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description General Report Contents - Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends - Market Drivers & Limiters for each chapter segment - Competitive Analysis for each chapte ...

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

Europe Market Overview for Diagnostic and Interventional Ophthalmic Devices 2017 - MedView

  • $ 4995
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description More integration was seen in the overall market for diagnostic and interventional ophthalmic devices. In the diagnostic space, practitioners are enjoying better, more flexible diagnostic capabilities ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.